MedTrace Logo

Spatial Repellents for Aedes-borne Virus Control in Sri Lanka

NCT05452447 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6949

Last updated 2025-09-15

No results posted yet for this study

Summary

The primary objective of the study is to demonstrate and quantify the protective efficacy (PE) of a single SR product, in reducing DENV infection and active Aedes-borne virus (ABV) disease in human cohorts. The study design will be a prospective, cluster randomized controlled trial (cRCT). Although not a specific objective of this project, an overall goal is to allow for official recommendations (or not) from the World Health Organization (WHO) for the use of SRs in public health. A WHO global policy recommendation will establish evaluation systems of SR products to regulate efficacy evaluations, thereby increasing quality, overall use and a consequent reduction in disease.

Conditions

  • Arbovirus Infections

Interventions

DEVICE

Transfluthrin

Passive emanator with formulated transfluthrin

DEVICE

Placebo

Passive emanator with formulated inert ingredients

Sponsors & Collaborators

  • S.C. Johnson & Son, Inc.

    collaborator INDUSTRY

  • fhiClinical

    collaborator UNKNOWN

  • Ministry of Health, Sri Lanka

    collaborator OTHER_GOV

  • University of Sri Jayewardenepura, Sri Lanka

    collaborator UNKNOWN

  • University of Washington

    collaborator OTHER

  • RemediumOne

    collaborator UNKNOWN

  • University of Notre Dame

    lead OTHER

Principal Investigators

  • John P Grieco, Ph.D. · University of Notre Dame

  • Korelege Hasitha Aravinda Tissera, M.D. · Epidemiology Unit, Ministry of Health, Sri Lanka

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-02
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • Sri Lanka

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05452447 on ClinicalTrials.gov